

Senate Bill 370

By: Senators Carter of the 1st, Bethel of the 54th, Jackson of the 2nd and Goggans of the 7th

**AS PASSED**

A BILL TO BE ENTITLED  
AN ACT

1 To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to  
2 controlled substances, so as to change certain provisions relating to Schedule I and V  
3 controlled substances; to provide for a short title; to change certain provisions relating to the  
4 definition of "dangerous drug"; to provide an effective date; to repeal conflicting laws; and  
5 for other purposes.

6 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

7 **SECTION 1.**

8 This 2012 Act which provides for the annual update of the identity of controlled substances  
9 and dangerous drugs is dedicated to the memory of Chase Corbitt Burnett and shall be known  
10 and may be cited as "Chase's Law."

11 **SECTION 2.**

12 Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled  
13 substances, is amended in Code Section 16-13-25, relating to Schedule I controlled  
14 substances, by adding a new subparagraph to paragraph (3) to read as follows:

15 "(GGG) Fluorophenylpiperazine (FPP);"

16 **SECTION 3.**

17 Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled  
18 substances, by revising paragraph (12) to read as follows:

19 ~~"(12) Any material, compound, mixture, or preparation which contains any quantity of~~  
20 ~~the following substances, their salts, isomers (whether optical, positional, or geometric),~~  
21 ~~homologues, and salts of isomers and homologues, unless specifically excepted,~~  
22 ~~whenever the existence of these salts, isomers, homologues, and salts of isomers and~~  
23 ~~homologues is possible within the specific chemical designation:~~

24 ~~(A) 1-pentyl-3-(1-naphthoyl)indole (JWH-018);~~

- 25 ~~(B) 1,1-dimethylheptyl-11-hydroxy-delta-8-tetrahydrocannabinol (HU-210; (6a,~~  
26 ~~10a)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydr~~  
27 ~~obenzo[c]chromen-1-ol);~~  
28 ~~(C) 2-(3-hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol (CP 47,497);~~  
29 ~~(D) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);~~  
30 ~~(E) 2-(2-Methoxyphenyl)-1-(1-pentylindole-3-yl) ethanone (JWH-250);~~  
31 ~~(F) 4-Methoxynaphthalen-1-yl-(1-pentylindole-3-yl) methanone (JWH-081).~~

32 Any of the following compounds, derivatives, their salts, isomers, and salts of isomers,  
33 unless specifically utilized as part of the manufacturing process by a commercial industry  
34 of a substance or material not intended for human ingestion or consumption, as a  
35 prescription administered under medical supervision, or research at a recognized  
36 institution, whenever the existence of these salts, isomers, and salts of isomers is possible  
37 within the specific chemical designation:

- 38 (A) Naphthoylindoles;  
39 (B) Naphthylmethylindoles;  
40 (C) Naphthoylpyrroles;  
41 (D) Naphthylideneindenes;  
42 (E) Phenylacetylindoles;  
43 (F) Cyclohexylphenols;  
44 (G) Benzoylindoles;  
45 (H) Tricyclic benzopyrans;  
46 (I) Adamantoylindoles;  
47 (J) Indazole amides;  
48 (K) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin  
49 -6-yl]-1-naphthalenylmethanone (WIN 55,212-2); or  
50 (L) Any compound, unless specifically excepted or listed in this or another schedule,  
51 structurally derived from 2-aminopropan-1-one by substitution at the 1-position with  
52 either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is  
53 further modified in any of the following ways:  
54 (i) By substitution in the ring system to any extent with alkyl, alkylendioxy, alkoxy,  
55 haloalkyl, hydroxyl, or halide substitutions, whether or not further substituted in the  
56 ring system;  
57 (ii) By substitution at the 3-position with an acyclic alkyl substitution; or  
58 (iii) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or  
59 methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic  
60 structure."

61 **SECTION 4.**

62 Said chapter is further amended in Code Section 16-13-29, relating to Schedule V controlled  
 63 substances, by deleting "or" at the end of paragraph (4), by replacing the period at the end  
 64 of paragraph (5) with "; or", and by adding a new paragraph to read as follows:

65 "(6) Ezogabine."

66 **SECTION 5.**

67 Said chapter is further amended in Code Section 16-13-71, relating to the definition of  
 68 dangerous drug, by adding new paragraphs to subsection (b) to read as follows:

69 "(14.5) Adenovirus;"

70 "(17.3) Aflibercept;"

71 "(17.7) Albiraterone;"

72 "(72.43) Azficel-T;"

73 (72.45) Azilsartan;"

74 "(78.3) Belatacept;"

75 (78.5) Belimumab;"

76 "(104.5) Boceprevir;"

77 "(106.5) Brentuxima vedotin;"

78 "(154.5) Centruroides [Scorpion] Immune;"

79 "(198.05) Clobazam;"

80 "(208.5) Coccidioides immitis;"

81 "(217.8) Crizotinib;"

82 "(386.05) Fidaxomicin;"

83 "(408.27) Gadobutrol;"

84 "(464.07) Icatibant;"

85 "(469.07) Indacaterol;"

86 "(487.06) Ioflupane;"

87 "(490.7) Ipilimumab;"

88 "(520.5) Linagliptin;"

89 "(842.18) Rilpivirine;"

90 "(843.825) Rivaroxaban;"

91 "(844.75) Roflumilast;"

92 "(885.5) Spinosad;"

93 "(931.553) Telaprevir;"

94 "(964.7) Ticagrelor;"

95 "(1025.2) Vandetanib;"

96 "(1027.55) Vemuranfenib;"

97 "(1030.5) Vilazodone;"

98 **SECTION 6.**

99 This Act shall become effective upon its approval by the Governor or upon its becoming law  
100 without such approval.

101 **SECTION 7.**

102 All laws and parts of laws in conflict with this Act are repealed.